Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.
Vasc Health Risk Manag
; 4(3): 493-505, 2008.
Article
en En
| MEDLINE
| ID: mdl-18827868
Previously, indirect thrombin inhibitors such as unfractionated heparin or low-molecular-weight heparin were used as a standard anticoagulation during percutaneous coronary intervention to prevent procedural thrombotic complications but at a risk of hemorrhagic complications. More recently, bivalirudin, a member of the direct thrombin inhibitor class, has been shown to have 1) predictable pharmacokinetics, 2) ability to inhibit free- and clot-bound thrombin, 3) no properties of platelet activation, 4) avoidance of heparin-induced thrombocytopenia, and 5) a significant reduction of bleeding without a reduction in thrombotic or ischemic endpoints compared to heparin and glycoprotein IIbIIIa inhibitors when used in patients presenting with acute coronary syndrome who are planned for an invasive treatment strategy.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fragmentos de Péptidos
/
Angioplastia Coronaria con Balón
/
Antitrombinas
/
Hirudinas
/
Síndrome Coronario Agudo
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Vasc Health Risk Manag
Asunto de la revista:
ANGIOLOGIA
Año:
2008
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Nueva Zelanda